Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells.
暂无分享,去创建一个
Kazunori Ohnishi | M. Fujie | Satoki Nakamura | S. Fujisawa | K. Ohnishi | K. Shibata | Satoki Nakamura | Tomonari Takemura | Lin Tan | Yasuyuki Nagata | Daisuke Yokota | Isao Hirano | Kazuyuki Shigeno | Kiyoshi Shibata | Michio Fujie | Shinya Fujisawa | Yasuyuki Nagata | Lin-Ya Tan | Tomonari Takemura | Daisuke Yokota | K. Shigeno | I. Hirano
[1] Bor Luen Tang,et al. Emerging roles for Rab family GTPases in human cancer. , 2009, Biochimica et biophysica acta.
[2] Shawn M. Sweeney,et al. Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. , 2000, Blood.
[3] A. Ganser,et al. Specific inhibition of bcr-abl gene expression by small interfering RNA. , 2003, Blood.
[4] P. Novick,et al. Role of Rab GTPases in membrane traffic and cell physiology. , 2011, Physiological reviews.
[5] Gordon B. Mills,et al. Derailed endocytosis: an emerging feature of cancer , 2008, Nature Reviews Cancer.
[6] D. Kobayashi,et al. Quantitative analysis of the anti-apoptotic gene survivin expression in malignant haematopoietic cells. , 2001, Anticancer research.
[7] D. Green,et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. , 1998, Blood.
[8] J. Goldenring,et al. Rab25 as a tumour suppressor in colon carcinogenesis , 2010, British Journal of Cancer.
[9] S. Park,et al. The role of p38 MAPK activation in auranofin‐induced apoptosis of human promyelocytic leukaemia HL‐60 cells , 2005, British journal of pharmacology.
[10] Zheng Zhao,et al. Delineation of the minimal commonly deleted segment and identification of candidate tumor‐suppressor genes in del(9q) acute myeloid leukemia , 2005, Genes, chromosomes & cancer.
[11] O. Witte,et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.
[12] Yun Dai,et al. A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2* , 2004, Journal of Biological Chemistry.
[13] D. Green,et al. Bcl-2-independent Bcr–Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL , 1998, Oncogene.
[14] E. Andreu,et al. Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–Dependent Expression of Bcl-XL , 2000, The Journal of experimental medicine.
[15] E. Canaani,et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia , 1985, Nature.
[16] Satoki Nakamura,et al. KIS induces proliferation and the cell cycle progression through the phosphorylation of p27Kip1 in leukemia cells. , 2008, Leukemia research.
[17] B. Calabretta,et al. Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation. , 2000, Blood.
[18] S. Derdak,et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. , 2005, Blood.
[19] T. Inaba,et al. Roles of Bim in Apoptosis of Normal and Bcr-Abl-Expressing Hematopoietic Progenitors , 2004, Molecular and Cellular Biology.
[20] A. Verma,et al. Role of the p38 Mitogen-activated Protein Kinase Pathway in the Generation of the Effects of Imatinib Mesylate (STI571) in BCR-ABL-expressing Cells* , 2004, Journal of Biological Chemistry.
[21] A. Verma,et al. Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib , 2009, Leukemia & lymphoma.
[22] T. Ueda,et al. Expression of the antiapoptotic gene survivin in chronic myeloid leukemia. , 2003, Anticancer Research.
[23] J U Gutterman,et al. The molecular genetics of Philadelphia chromosome-positive leukemias. , 1988, The New England journal of medicine.
[24] L Bibbs,et al. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. , 1994, Science.
[25] N. Gruis,et al. Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma. , 2008, Investigative ophthalmology & visual science.
[26] P. Nowell,et al. DNA Contents of Chromosome Ph1 and Chromosome 21 in Human Chronic Granulocytic Leukemia , 1964, Science.
[27] J. Melo,et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. , 1997, Blood.
[28] C. Sawyers,et al. Signal transduction by wild-type and leukemogenic Abl proteins. , 1997, Biochimica et biophysica acta.
[29] J. Pereira-Leal,et al. Evolution of the Rab family of small GTP-binding proteins. , 2001, Journal of molecular biology.
[30] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[31] D. Cortez,et al. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis , 1995, Molecular and cellular biology.
[32] G. Daley,et al. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.
[33] D. Altieri,et al. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.
[34] B. Druker,et al. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. , 2005, Cancer research.
[35] O. Witte,et al. Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. , 2003, Blood.
[36] M. Hengartner. The biochemistry of apoptosis , 2000, Nature.
[37] Osamu Miura,et al. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. , 2009, Cancer research.
[38] H. J. Kim,et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. , 2001, Biochemistry.
[39] J. Sampath,et al. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. , 2005, Cancer research.
[40] E. Lam,et al. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells , 2005, Oncogene.
[41] I. Weissman,et al. Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[42] H. Kajiho,et al. Characterization of Rab45/RASEF containing EF-hand domain and a coiled-coil motif as a self-associating GTPase. , 2007, Biochemical and biophysical research communications.
[43] John Calvin Reed,et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. , 2000, Neoplasia.
[44] Jukka Westermarck,et al. Phosphatase‐mediated crosstalk between MAPK signaling pathways in the regulation of cell survival , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[45] S. Pfeffer. A model for Rab GTPase localization. , 2005, Biochemical Society transactions.
[46] J. Melo,et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.
[47] I. McNeish,et al. Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy , 2003, Oncogene.
[48] F. Durrieu,et al. Bcr-abl translocation can occur during the induction of multidrug resistance and confers apoptosis resistance on myeloid leukemic cell lines , 1997, Cell Death and Differentiation.
[49] J. Goldenring,et al. Regulation of Vesicle Trafficking in Madin-Darby Canine Kidney Cells by Rab11a and Rab25* , 2000, The Journal of Biological Chemistry.
[50] Satoki Nakamura,et al. The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. , 2010, Carcinogenesis.
[51] G. Mills,et al. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers , 2004, Nature Medicine.
[52] G. Pagès,et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function , 2003, Oncogene.
[53] W. El-Deiry,et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. , 1995, Blood.